After Hours
$
0.84
Change
+0.02 +2.03%
Volume
Volume 817
Jun 28, 2022, 6:57 p.m.
Quotes are delayed by 20 min
Today's close
$ 0.82
$ 0.82
Change
+0.0031 +0.38%
Day low
Day high
$0.82
$0.85

52 week low
52 week high
$0.71
$1.89

Market cap
$72.59M
Average volume
322,223
P/E ratio
N/A
Rev. per Employee
$1.24M
EPS
-0.01
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on LPCN
-
Lipocine shares plummet 35% after FDA fails to approve its testosterone replacement therapy
- Emma Court
-
Lipocine downgraded to hold from buy at Canaccord
- Tomi Kilgore
-
Lipocine stock price target cut to $2 from $11 at Canaccord
- Tomi Kilgore
-
Bed Bath & Beyond surges on earnings
- MarketWatch
Analyst Ratings
Other News on LPCN
-
- Edgar Online - (EDG = 10Q, 10K)
-
MVIS, MRIN and CLVR among mid-day movers
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
- Edgar Online - (EDG = 10Q, 10K)
-
BGVF, VYNT and SNMP among pre market gainers
- Seeking Alpha
-
Warning: LPCN is at high risk of performing badly
- Seeking Alpha
-
AG, FRO and WATT among pre market gainers
- Seeking Alpha
-
FDA affirms class 1 NDA resubmission for Lipocine's Tlando
- Seeking Alpha
-
Lipocine discloses mid-stage data for NASH candidate
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
- Loading more headlines...
Press Releases on LPCN
-
LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS
- PR Newswire - PRF
-
LIPOCINE ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE
- PR Newswire - PRF
-
Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results
- PR Newswire - PRF
-
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022
- PR Newswire - PRF
-
Lipocine Announces Financial Results for the Year Ended December 31, 2021
- PR Newswire - PRF
-
Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH
- PR Newswire - PRF
-
Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference
- PR Newswire - PRF
-
Lipocine to Present at The H.C. Wainwright 5th Annual NASH Investor Conference
- PR Newswire - PRF
-
Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO®
- PR Newswire - PRF
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com